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The assessment of 3-indole lactate as promising antimalarial agent 







• Most threatening and devastating human 
parasitic vector-borne disease
• Plasmodium falciparum  resistance  nearly to 
all current antimalarial drugs
• Side effects of anti-malarial drugs  sulfadoxin
chloroquine, quinine, and pyremethamine
• Increasing in number of malaria cases                      
due to unavoidable factors:
(a) Wide spread of vector & parasite
(b) P. knowlesi  new emerging spp.
(c) Uncontrolled immigrant activity.
(d) Antimalarial drug resistance strain
STREPTOMYCES
• Filamentous Gram (+ve) bacteria, high genomic 
G-C content and spores producer
• 85 % out of 500 species produced 2/3 of today’s 
well known clinical antibiotics such as streptomycin, 
tetracycline,  erythromycin, amphotericin B, ivermectin, 
chloramphenicol, vancomycin, hygromycin  profits 
to pharmaceutical company                                         
• Some species living endophytically in the plants 
or other organisms
• Present study: Streptomyces SUK10 living                           





- Meranti kepong (Malay)
- Meranti merah (Sumatra)







Rich with many compounds with 
promising bioactivities :
- Triterpenoid  good antifungal 
(Saraswathy et al. 1992)
- Hemsleyanols  agent for 
chemopreventive (Tanaka et 
al. 2001)
- Hopeaphenol  antidysentery
(Subramaniam et al, 2015)
- α-Viniferin  cytotoxicity 
agent (Rohaiza et al. 2011)
- Acuminatol  antioxidant 
(Muhammad et al. 2012)
- Vaticanol B  antibacterial 
activity (Basri et al. 2012)
Present study  focused on 
the bark of S. ovalis tree
OBJECTIVES
1. To analyze the chemical structure of bioactive compound isolated   
from endophytic Streptomyces SUK10  strain lived in the bark of 
Shorea ovalis tree.
2. To assess the in-vivo antimalarial activity of                                                 
3-indole lactate  isolated from Shorea ovalis
3. To determine the in-vivo toxicity test of 3-indole 
lactate in mice.

SUK 10 CRUDE EXTRACT PRODUCTION
3-5 block of (5x5)mm ISP2 
agar enriched with isolates 
400 mL NB  on orbital 
shaker (200 rpm, RT)
To produce ethyl acetate-crude extract of Streptomyces SUK10
After 7 -14 days
Filtration  extract                               
the supernatant (sp) 
for 3x with ethyl 
acetate (EA)                    






SUK10 CRUDE EXTRACT FRACTIONATION
• Instrument: Biotage Flash Chromatography (GRACE REVELERIS)
- Mobile phase : Hexane (A) & Ethyl acetate (B)
- SUK10 crude extract net weight : 2.8 g
- Column : Generic Silica 40 g
- Elution flow rate : 35 mL/minute
- Run length : 80 minutes
- UV1 wavelength absorption : 254 nm
- UV2 wavelength absorption : 310 nm
TLC, NMR & HR-LCMS
• NMR Solvent : Chloroform-D
• Test : 1H, C13, HMBC, HMQC, Depth, 
COSY (400Mz) & ROESY (600Mz)
• All samples were sent for HR-LCMS
• Info obtained : RT, molecular formula & 
weight and compound name & data
• Comparison : AntiBase Library (Version 
2013)
• TLC solvent system :
- 70-H : 30-EA (V1 – V3)
- 80-H : 20-EA (V4 – V10)
- 40-H : 60-EA (V11 – V18)
- 98-DCM : 2-M (V19 – V22)
ANTIMALARIAL ACTIVITY OF 3-INDOLE LACTATE
• Concentration (doses of 0.1 ml)
~  50 µl/kg bw (1x)
~  25 µl/kg bw (1/2x)
~  12.5 µl/kg bw (1/4x)
~  6.25 µl/kg bw (1/8x)
~  3.125 µl/kg bw (1/16x)
• (+ve) control : 0.1 ml of 10 mg/kg dH2O diluted CH
• (-ve) control : 0.1 ml of 0.9% normal saline
• 4D suppression test
~  Parasitemia density (%) 
~  Parasitemia inhibition (%) 
~  Survival time (day)
• Parasite : Plasmodium berghei NK65
• Mice : ICR / ♂ / 25-30 g / 6-8 weeks / ad-libitium feed
(A) (B) (C)
(D) (E) (F)
PARASITE ADMINISTRATION AND ANIMAL TAGGIING
(A) (B) (C)
(D) (E) (F)




BIOCHEMICAL TOXICITY  TEST AND ORGAN HISTOLOGY

TLC
22 combine fractions 
out of 123 fractions 
number were 
obtained and                            
labeled as                   
V1 – V22 






V1 2 – 10 0.1106
V2 11 – 15 0.0271
V3 16 – 25 0.8132
V4 26 – 30 0.1255
V5 31 – 36 0.0890
(80-H : 20-EA)
V6 37 – 42 0.0393
V7 43 – 48 0.0162
V8 49 – 55 0.0185
V9 56 – 63 0.0125
V10 64 – 71 0.0301
(40-H : 60-EA)
V11 72 – 75 0.0249
V12 76 – 81 0.0287
V13 82 – 86 0.0283
V14 87 - 92 0.0191
(90-DCM : 10-M)
V15 93 – 98 0.0162
V16 99 – 100 0.0113
V17 101 – 103 0.0276
V18 104 0.0082
V19 105 – 110 0.0300
V20 111 – 116 0.0498
V21 117 – 119 0.0142
V22 120 – 123 0.0184
NMR & HR-LCMS
• NMR spectrum analysis :
- V3 = V4
- V5 = V6
- V7 = V8
- V12 = V13
- V15 = V22
• Structure analysis :
- V2 to V8 = long carbon chain (triglyceride fatty acids)
- V11 = promising pure compound based on:
- 1H NMR analyses
- promising net weight (g) in TLC 
- interesting signals/peaks (corresponding to major constituent)
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ANTIMALARIAL ACTIVITY OF 3-INDOLE LACTATE
Parasitemia density (%) of the mice treated with 3-indole lactate






























0.1 mL of 0.9% 
normal saline (NS)
ANTIMALARIAL ACTIVITY OF 3-INDOLE LACTATE
Inhibition Rate (%) of the mice treated with 3-indole lactate









































(*) Inhibition rate at >70 % is considered as having antimalarial activity
ANTIMALARIAL ACTIVITY OF 3-INDOLE LACTATE
Survival Time (days) of the mice treated with 3-indole lactate








0.1 mL of 0.9% 
normal saline (NS)


























































































6.80   
± 3.06
5.8 – 9.5 g/dL
TA : Sub-acute regime – Daily treatment (28 days) 
TB : Sub-acute regime – Daily treatment (28 days) 2 hours post-infection
TC : Sub-chronic regime – Daily treatment (90 days)
TD : Sub-chronic regime – Daily treatment (90 days) 2 hours post-infection
CN : Control regime – Normal mice without infection and treatment
CI : Control regime – Infected mice on D0
ALT : Alanine aminotransferase
AST : Aspartate transaminase
ALP : Alkaline phosphatase
STP : Serum total protein
(*) All values were expressed as  
mean ± standard errors (se)
(*) All NR values were referred from  
Research Animal Resources, 
University of Minnesota, USA




ControlTreatment (Acute) Treatment (Sub-acute)
ORGAN HISTOLOGY FOR TOXICITY ASSESSMENT

CONCLUSION
• 50% of the mice treated at 3.125 µg kg-1 bw 3-indole lactate were survive up to
≥100 days post-infection  one quarter of normal mice life span (Sage et al. 2010;
Szenczi et al. 2012).
• No toxicity effects were discovered on the hosts treated with 3-indole lactate at all
concentrations
• Naturally, indole lactate produced by many endophyte microorganisms and
displayed a wide diversity of structures and biological functions (Samaoui et al.
2012)  making 3-indole lactate as useful chemical entity for the discovery and
development of new drugs.
• 3-indole lactate derivatives were already demonstrated to have a good biological
activities  antibacterial, antiviral, antitumor, fungicidal, herbicidal , etc.. (Magyar et
al. 1999).
• Although 3-indole lactate was previously reported from other Streptomyces sp.
(Rhee 2002, Ben Ameur Mehdi et al. 2004, Bin et al. 2009), its antimalarial
properties has not been revealed.

FUTURE WORKS
1. Identifying biosynthesis pathways of 3-indole lactate in 
Streptomyces gene cluster 
2. Determine the mechanism of action of 3-indole lactate
3. Play around with different concentrations of 3-indole lactate 
to determine therapeutic dosage
4. Consider curative and preventive regimes of the treatment 
5. In-vitro antimalarial activities of  the compound
6. Screening towards any other MDR agents (M. tuberculosis, 
MRSA, VRSA, etc..)
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